Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
20 participants
INTERVENTIONAL
2026-01-01
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Robot assisted gait training combined with Transcutaneous spinal cord stimulation
Robot-assisted gait training and transcutaneous spinal cord stimulation in chronic non-ambulatory stroke survivors: pilot RCT trial
Participants in the experimental group will receive 30 minutes of robot assisted gait training (RAGT) transcutaneous spinal cord stimulation 3 times per week, 8 weeks, totaling 24 sessions. The gait training will utilize a treadmill equipped with a partial-body-weight support system and a lab-developed RAGT device. The RAGT protocol will be the same as in the control group
Robot assisted gait training alone
Robot assisted gait training alone
Participants in the control group will receive 30 minutes of assisted gait training (RAGT), 3 times per week, for 8 weeks, totaling 24 sessions. The gait training will utilize a treadmill equipped with a partial-body-weight support system and a lab-developed RAGT device
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Robot-assisted gait training and transcutaneous spinal cord stimulation in chronic non-ambulatory stroke survivors: pilot RCT trial
Participants in the experimental group will receive 30 minutes of robot assisted gait training (RAGT) transcutaneous spinal cord stimulation 3 times per week, 8 weeks, totaling 24 sessions. The gait training will utilize a treadmill equipped with a partial-body-weight support system and a lab-developed RAGT device. The RAGT protocol will be the same as in the control group
Robot assisted gait training alone
Participants in the control group will receive 30 minutes of assisted gait training (RAGT), 3 times per week, for 8 weeks, totaling 24 sessions. The gait training will utilize a treadmill equipped with a partial-body-weight support system and a lab-developed RAGT device
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. All genders included.
3. Chronic ischemic or hemorrhagic stroke \>=6 months, with limited within-home comfortable walking speed \<= 0.49 m/s and unable to walk independently in community (FAC \<= 3)
4. Able to communicate with investigators, follow 2-step command, and correctly answer consent comprehension questions in English.
5. Currently not participating in treadmill walking exercises or exercises involving weight-bearing activities.
6. Have physicians' approval for exercise and be in a stable medical condition
Exclusion Criteria
2. Have musculoskeletal disorders that prevent the participant from participating in the exercise
3. Blood pressure higher than 200/110 mm Hg
4. Significant ataxia or unilateral spatial neglect (score of 2 on NIH stroke scale item 7 or 11)
5. Reported pain that limits or interferes with activities of daily living and physical activity/exercise
6. Diagnosis of other neurological diseases (multiple sclerosis, Alzheimer's disease, Parkinson's disease)
7. Diagnosis of severe depression (HADS score 15-21)
8. Unable to speak or understand English, and travel to the research laboratory.
9. Contraindications to tSCS and TMS
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Kansas Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wen Liu, Ph.D.
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wen Liu, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Kansas Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Neuromuscular Research Laboratory
Kansas City, Kansas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Mustapha Mangdow, PT, MS
Role: primary
Wen Liu, PhD
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STUDY00162114
Identifier Type: -
Identifier Source: org_study_id